Linked Data API

Show Search Form

Search Results

1521789
registered interest false more like this
date less than 2022-10-13more like thismore than 2022-10-13
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading NHS: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if she will make a comparative estimate of the annual savings that (a) unbranded generic, (b) branded generic and (c) biosimilar medicines have contributed to the NHS drug bill compared to branded prices had those medicines not been available for each year since 2012 for which data is available. more like this
tabling member constituency Harlow remove filter
tabling member printed
Robert Halfon more like this
uin 62793 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2022-10-25more like thisremove minimum value filter
answer text <p>The current Voluntary Scheme for Branded Medicines Pricing and Access expenditure forecast assumes that average spend at patent expiry will decrease by 70% for a non-biologic medicine or 45% for a biologic medicine. The Secretary of State has also commissioned further policy advice on this matter. These assumptions will be reviewed ahead of the negotiation of a new Scheme.</p> more like this
answering member constituency Newark more like this
answering member printed Robert Jenrick more like this
question first answered
less than 2022-10-25T14:44:42Zmore like thismore than 2022-10-25T14:44:42Z
answering member
4320
label Biography information for Robert Jenrick more like this
tabling member
3985
label Biography information for Robert Halfon more like this